Loading
A phase 3 trial of Ivonescimab, Pemetrexed, Carboplatin in non-small-cell lung cancer, run by Summit Therapeutics, active and no longer recruiting.
Phase III Study of AK112 for NSCLC Patients is a phase 3 interventional study registered as NCT06396065 by Summit Therapeutics, with 420 participants enrolled, started 2023-05-04 and due to reach its primary completion in 2025-04-12. Interventions recorded: AK112 Injection, Placebo Injection. Conditions listed: Non-Squamous Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Summit Therapeutics, Ivonescimab, Pemetrexed, Platinum agents.
Shares Summit Therapeutics, Ivonescimab, Pemetrexed, Platinum agents.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Platinum agents, Carboplatin.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Platinum agents, Carboplatin.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Platinum agents, Carboplatin.
Shares Pemetrexed, Platinum agents, Carboplatin, Cytotoxic chemotherapy.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Platinum agents, Carboplatin.
Shares Pemetrexed, Platinum agents, Carboplatin, Cytotoxic chemotherapy.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/